Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1NSCLC 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Liposarcoma 1Hodgkin Disease 1Disease Progression 1Carcinoma in Situ 1

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2durvalumab 2Nivolumab 2Gemcitabine 2Doxorubicin 2Dexamethasone 2tremelimumab 1tivozanib 1ricolinostat 1pomalidomide 1nilotinib 1capivasertib 1Zoledronic Acid 1Vitamin D 1Taxes 1Oxaliplatin 1Leucovorin 1Lenalidomide 1Fulvestrant 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1Cisplatin 1Calcium 1Bortezomib 1AZD 6244 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Disease Progression × Clinical Trials, Phase I as Topic × Clear all
NCT04503265 2025-05-01

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AtlasMedx, Incorporated

Phase 1/2 Recruiting
122 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡